MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)

Sponsor
UMC Utrecht
Study ID
NCT05937958
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of this observational study is to explore the effectiveness and side effects of a high dose daily adapted SBRT (stereotactic body radiotherapy) boost delivered with MRLinac in patients with gynaecological cancers that cannot receive a brachytherapy boost to the primary tumour for different reasons (medical conditions, tumour extensions, etc). Current alternative for brachytherapy in these situations is often a non-adaptive conebeam- CT guided boost. Conebeam-CT guided non-adaptive high dose SBRT in under these circumstances is described being quite toxic. The main questions this study aims to answer are: * In how many cases could local control (i.e. total disappearance of the tumor) is be achieved with this treatment? * Which side effects are observed in patients receiving this treatment? Participants will be asked to fill out questionnaires (e.g. regarding side effects). Furthermore, participants are asked if their clinical data may be used for study purposes.

Key Dates

First listed
Jul 10, 2023
Start date
Apr 1, 2023
Status verified
Jul 2023
Primary completion
Oct 1, 2025
Completion
Oct 1, 2027

Study Design

Enrollment
30 participants (estimated)

Primary Outcome Measure

Local control [ Time Frame: 3 months after MRLinac treatment ]

Central Contacts

Find similar trials

Nationwide
Cervical cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies